Ashwath Jayagopal Sells 3,719 Shares of Opus Genetics (NASDAQ:IRD) Stock

Opus Genetics, Inc. (NASDAQ:IRD) insider Ashwath Jayagopal sold 3,719 shares of the firm’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $5.12, for a total transaction of $19,041.28. Following the transaction, the insider directly owned 516,775 shares in the company, valued at approximately $2,645,888. This represents a 0.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Opus Genetics Stock Down 1.7%

Shares of NASDAQ:IRD opened at $4.58 on Friday. Opus Genetics, Inc. has a 12-month low of $0.65 and a 12-month high of $5.30. The company’s 50 day moving average price is $3.41 and its two-hundred day moving average price is $2.42. The firm has a market cap of $325.87 million, a PE ratio of -5.59 and a beta of 0.45.

Analysts Set New Price Targets

A number of equities analysts have commented on IRD shares. Wall Street Zen upgraded Opus Genetics from a “sell” rating to a “hold” rating in a research note on Sunday, March 1st. Chardan Capital upped their target price on Opus Genetics from $9.00 to $11.00 and gave the company a “buy” rating in a research report on Thursday, March 12th. Wedbush increased their target price on Opus Genetics from $8.00 to $10.00 and gave the stock an “outperform” rating in a report on Thursday, March 12th. B. Riley Financial assumed coverage on Opus Genetics in a research note on Wednesday, December 10th. They issued a “buy” rating and a $9.00 price target for the company. Finally, BTIG Research upped their price objective on shares of Opus Genetics from $7.00 to $12.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $9.33.

More Opus Genetics News

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: Analyst support has been strengthening: Oppenheimer initiated coverage (outperform) and other firms (BTIG, Wedbush, Craig Hallum) have raised targets, lifting longer‑term upside expectations for IRD. Read More.
• Neutral Sentiment: Institutional buying and position changes were reported (several funds added or increased stakes), which may support demand over time but do not guarantee immediate price support. Read More.
• Neutral Sentiment: Technical/liquidity context: trading volume today is below average, the 50‑day and 200‑day moving averages are above the 200‑day, and the 12‑month range ($0.65–$5.30) frames near resistance — useful for timing trades but not a catalyst by itself. Read More.
• Negative Sentiment: Clustered insider selling on March 16 is a likely principal driver of the pullback: CEO George Magrath sold 24,438 shares (~$127k), COO Joseph Schachle and other executives sold several thousand shares each. These filings (Form 4s) signal modest reductions in insider stakes and likely put near‑term downward pressure on the stock. Read More. Read More.

Hedge Funds Weigh In On Opus Genetics

Hedge funds and other institutional investors have recently modified their holdings of the business. Blair William & Co. IL raised its holdings in shares of Opus Genetics by 12.3% during the 4th quarter. Blair William & Co. IL now owns 27,466 shares of the company’s stock worth $55,000 after buying an additional 3,000 shares in the last quarter. Raymond James Financial Inc. boosted its stake in Opus Genetics by 95.6% in the third quarter. Raymond James Financial Inc. now owns 22,508 shares of the company’s stock valued at $37,000 after buying an additional 11,000 shares in the last quarter. Occudo Quantitative Strategies LP bought a new position in Opus Genetics in the fourth quarter valued at about $25,000. Virtu Financial LLC acquired a new position in Opus Genetics during the fourth quarter worth about $34,000. Finally, Johnson Investment Counsel Inc. acquired a new position in Opus Genetics during the fourth quarter worth about $40,000. Institutional investors own 14.97% of the company’s stock.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.